News & Press Release Distribution Service
FDA questions new info about Eli Lilly’s Cymbalta, cancels review meeting
2010-01-06 01:08:17 (GMT) (Caymanmama.com - Business Health News News)
Detroit, Michigan (CaymanMama.com) — Cymbalta, a drug by Indianapolis based Eli Lilly & Co., is an antidepressant typically used to treat depression, generalized anxiety disorder, diabetic nerve pain and fibromyalgia.
On Tuesday, the Food and Drug Administration canceled a meeting to review the antidepressant for a new treatment use for chronic pain, stating the Jan. 28 meeting would be called off “to allow time for the FDA to review new information,” about the proposed use, according to an official statement.
According to the Associated Press, “Lilly withdrew an application in November 2008 after FDA reviewers questioned the methodology and dosing in some of the company’s trials.”
Lilly then resubmitted a new application with an enclosed study of Cymbalta’s possible use for chronic pain caused by osteoarthritis, along with new information from a study of lower back pain.
Cymbalta is the drug-makers second-best selling product, following the anti-psychotic Zyprexa, having brought in $2.24 billion in sales through the the majority of 2009.
Eli Lilly & Co. is working overtime to protect the impending expiration of Cymbalta’s patent which ends in 2013.
CaymanMama.com - Press Release Distribution Service
Comments
Articles
- Website design elements that work for your business by Dallas website design company
- Returning to work after the drug rehabilitation process by Canada Drug rehabilitation center
- Drug addiction - Why do drugs influence people?
- Prostate cancer - Things to know
- New York car accident claims - no fault, uninsured or underinsured claims
- Been in a motorcycle accident? Vehicle and Motorcycle accident lawyer educates
- Pakistani youth deprived of recreational facilities
- How to Identify a Brain Injury
- Bluetooth technology: Revolutionized
- Color card printing best for business promotion and personal use
